Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years

Scalabre, Aurélien; Philippe‐Chomette, Pascale; Passot, Guillaume; Orbach, Daniel; Élias, Dominique; Corradini, Nadège; Brugières, Laurence; Msika, Simon; Leclair, Marc‐David; Joseph, S.; Brigand, Cécile; Baudin, François; Soler, Christine; Pezet, Denis; Gagnière, Johan; Gléhen, Olivier; Sarnacki, Sabine

doi:10.1002/pbc.26934

Cited by 15 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is a considerable lack of data regarding the best treatment strategy in the pediatric population. The use of CRS‐HIPEC for the treatment of DMPM was reported before in only 13 pediatric cases, with favorable outcomes 3,5,33,37 . Our study confirms that CRS‐HIPEC could be used as first‐line treatment in children with resectable disease who are fit for major surgery 37‐39 .…”

Section: Discussionsupporting

confidence: 79%

“…The development of CRS and HIPEC has improved survival of rare tumors of the peritoneum. Among tumors treated with CRS‐HIPEC, mesotheliomas are associated with a better overall survival and disease‐free survival than other rare tumors as desmoplastic small round cell tumors 33 . Regarding patients treated before 1990, the therapeutic strategy does not seem clearly established.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multicystic and diffuse malignant peritoneal mesothelioma in children

Vermersch

Arnaud

Orbach

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Background: Malignant and multicystic peritoneal mesotheliomas are extremely rare tumors in children, developing from mesothelial cells. No specific guidelines are available at this age. Methods: We performed a retrospective analysis of all identified children (< 18-year-old) treated in France from 1987 to 2017 for a diffuse malignant peritoneal mesothelioma (DMPM) or a multicystic peritoneal mesothelioma (MCPM). Results: Fourteen patients (5 males and nine females), aged 2.2 to 17.5 years, were included. The most frequent presenting symptoms were abdominal pain, ascitis, and alteration in the general condition. Eight patients had epithelioid mesothelioma, three had biphasic mesothelioma, and three had MCPM. Eight patients with DMPM diagnosis received cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Among them, six patients had neoadjuvant systemic chemotherapy, one patient, post-operative chemotherapy, and one patient CRS and HIPEC only. Three patients received only systemic chemotherapy. All patients with MCPM had only surgery. After a median follow-up of seven years (2-15), six patients (6/11; one death) with DMPM and two patients (two/three) with MCPM had a local and distant recurrences. Conclusion: Peritoneal mesothelioma in children is a rare condition with difficult diagnosis and high risk of recurrence. Worldwide interdisciplinary collaboration and networking are mandatory to help diagnosis and provide harmonious treatment guidelines.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Multicystic and diffuse malignant peritoneal mesothelioma in children

Vermersch

Arnaud

Orbach

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) initially used for peritoneal carcinomatosis have also been tried in children with peritoneal sarcomatosis, including RMS, with modest results . Twenty‐one patients with peritoneal sarcoma (one with RMS) were reported to have received CRS and HIPEC in a French nationwide study, the outcome was not encouraging apart from in patients with mesothelioma. Similarly, a 50‐patient series (7 with RMS) reported poor outcome of CRS and HIPEC in RMS patients …”

Section: Discussionmentioning

confidence: 99%

Managing peritoneal involvement in children and young people with rhabdomyosarcoma: A single‐center experience from the United Kingdom

Moulik

Vaidya

Mandeville

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

We describe our experience in managing nine children and adolescents with rhabdomyosarcoma (RMS) and peritoneal involvement. The radiological pattern of peritoneal involvement was diverse from only ascites to solid peritoneal mass/omental caking. Treatment included systemic chemotherapy in all, surgery in three, and radiotherapy in eight. Two patients with presumed nonmalignant ascites, no solid peritoneal metastasis, nonalveolar histology, near‐complete resection of residual disease, and radiotherapy survived long term. One patient has just completed treatment, and the remaining six relapsed/progressed at the time of reporting. Five of six patients died after a median of 5 (3–7) months from relapse despite second‐line chemotherapy.

show abstract

“…В 2017 году A. Scalabre и соавт. опубликовали серию наблюдений 22 пациентов в возрасте до 18 лет, получивших лечение с HIPEC во Франции с 2001 по 2015 год [46]. В это исследование включили 9 клинических случаев, опубликованных ранее F. Bautista и соавт.…”

Section: мировой опыт применения циторедукции и Hipec у детейunclassified

“…Немецкие исследователи применяют доксорубицин из расчета 15 мг/м 2 [48]. Группа французских авторов опубликовала опыт применения более высоких доз препаратов: оксалиплатин -300 мг/м 2 (до 460 мг/м 2 ) и иринотекан -200 мг/м 2 , что демонстрирует удовлетворительную переносимость интраперитонеальной химиоперфузии у детей даже при использовании высоких доз препаратов [44,46]. Разнятся и методологические особенности проведения процедуры -время гипертермической химиоперфузии и температура используемого раствора.…”

Section: заключениеunclassified

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in children

Ахаладзе

Rabaev

Grachev

2019

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) is treatment of choice for determined group of adult patients. Cytoreduction and HIPEC is usually used in patients with ovarian, gastric and colorectal cancer, appednix cancer, peritoneal mesothelioma and in some tumors of another localization. The experience of cytoreductive surgery and HIPEC in childhood is limited due to the lower frequency of peritoneal carcinomatosis in pediatric population. However, about 30% of malignant tumors in children develop in peritoneal cavity and pelvis. High recurrence rate are typical for these tumors, particularly due to tumor rupture. Taking into consideration low frequency of epithelioid tumors in children HIPEC is used for patients with other tumor types such as desmoplastic small round cell tumor (DSRCT), germ cell tumors, rhabdomyosarcoma and others. The aim o this paper is the review of the literature and present experience analysis of cytoreductive surgery and HIPEC in children.

show abstract

Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years

Abstract: In this national series, outcomes of HIPEC are encouraging for the treatment of peritoneal mesothelioma in children.

Cited by 15 publications

References 28 publications

Multicystic and diffuse malignant peritoneal mesothelioma in children

Multicystic and diffuse malignant peritoneal mesothelioma in children

Managing peritoneal involvement in children and young people with rhabdomyosarcoma: A single‐center experience from the United Kingdom

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in children

Contact Info

Product

Resources

About